Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
December 23, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. ...
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET | VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...